A Clinical Study of GC012F Injection in High-risk, Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
| Title | A Clinical Study of GC012F Injection in High-risk, Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma |
|---|---|
| Description | This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.. 22 evaluable subjects were dosed. |
| Organism | Homo sapiens |
| Data Type | Genetic Biomarkers |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA025163 |
| Release Date | 2024-04-12 |
| Submitter | siyu huang (siyu.huang@gracellbio.com) |
| Organization | Gracell Biotechnologies (Shanghai) Co., Ltd. |
| Submission Date | 2024-04-10 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006209-02 | TE NDMM | 2 | Genetic Biomarkers | 27.5 KB | zip | 0 | Unavailable |